The Valley Desk

NCT04459715 · Interventional trial

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Overall registry status Terminated

Phase 3

Conditions Squamous Cell Carcinoma of the Head and Neck

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov